Prof. Jie Chen 陈洁
Chief Physician, Professor
Neuroendocrine Tumor Center, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of neuroendocrine tumors, including gastrointestinal, pancreatic, and hereditary types such as MEN1/2/4, VHL syndrome, and NF1.
Dr. Chen is Director of the Neuroendocrine Tumor Center at Fudan University Shanghai Cancer Center. Dr. Chen earned a medical doctorate from Sun Yat-sen University in 2002, completed postdoctoral research in Germany, and studied in the UK. Since joining Fudan in 2021, Dr. Chen has led multidisciplinary care for neuroendocrine tumors. Research includes epidemiology, molecular markers, and treatment guidelines published in journals such as J Clin Oncol.
Professional roles
- Chair (Designate), Neuroendocrine Tumor Professional Committee, China Anti-Cancer Association
- Advisory Board Member, European Neuroendocrine Tumor Society (ENETS)
- Member, Neuroendocrine and Endocrine Tumors Group, European Society for Medical Oncology (ESMO)
- Medical Advisory Committee Member, International Neuroendocrine Cancer Alliance (INCA)
Name order: in Chinese the family name comes first (Chen Jie). Papers usually list the name as Jie Chen or Chen J.
Selected publications
98 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Sci (Weinh), 2026 (senior author): Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression. PubMed 41972414
- World J Surg Oncol, 2026 (senior author): Correction: PTEN suppresses renal cell carcinoma proliferation and migration via inhibition of the PI3K/AKT pathway. PubMed 41845486
- Endocr Relat Cancer, 2026 (senior author): Systemic therapy for advanced pheochromocytoma and paraganglioma: real-world evidence from a single-center cohort. PubMed 41543031
- Eur J Surg Oncol, 2025 (first author): Reply to: Re: Optimizing surgical timing following neoadjuvant therapy for gastric cancer: Insights from a multicenter retrospective analysis. PubMed 40570660
- Eur J Surg Oncol, 2025 (first author): Optimizing surgical timing following neoadjuvant therapy for gastric Cancer: Insights from a multicenter retrospective analysis. PubMed 40288218
- World J Surg Oncol, 2025 (senior author): PTEN suppresses renal cell carcinoma proliferation and migration via inhibition of the PI3K/AKT pathway. PubMed 39910585
- Biochim Biophys Acta Rev Cancer, 2024 (senior author): Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors. PubMed 39303858
- Oncologist, 2023 (senior author): The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. PubMed 37086484
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion